282 related articles for article (PubMed ID: 32486283)
1. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
Fernandes RS; Freire MCLC; Bueno RV; Godoy AS; Gil LHVG; Oliva G
Viruses; 2020 May; 12(6):. PubMed ID: 32486283
[TBL] [Abstract][Full Text] [Related]
2. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
He X; Quan S; Xu M; Rodriguez S; Goh SL; Wei J; Fridman A; Koeplinger KA; Carroll SS; Grobler JA; Espeseth AS; Olsen DB; Hazuda DJ; Wang D
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33766889
[TBL] [Abstract][Full Text] [Related]
3. Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms.
Kato F; Hishiki T
Viruses; 2016 May; 8(5):. PubMed ID: 27164125
[TBL] [Abstract][Full Text] [Related]
4. Zika Virus Replicons for Drug Discovery.
Xie X; Zou J; Shan C; Yang Y; Kum DB; Dallmeier K; Neyts J; Shi PY
EBioMedicine; 2016 Oct; 12():156-160. PubMed ID: 27658737
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 replicon for high-throughput antiviral screening.
Zhang QY; Deng CL; Liu J; Li JQ; Zhang HQ; Li N; Zhang YN; Li XD; Zhang B; Xu Y; Ye HQ
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33956592
[TBL] [Abstract][Full Text] [Related]
6. Viral replicons as valuable tools for drug discovery.
Hannemann H
Drug Discov Today; 2020 Jun; 25(6):1026-1033. PubMed ID: 32272194
[TBL] [Abstract][Full Text] [Related]
7. West Nile virus infectious replicon particles generated using a packaging-restricted cell line is a safe reporter system.
Li W; Ma L; Guo LP; Wang XL; Zhang JW; Bu ZG; Hua RH
Sci Rep; 2017 Jun; 7(1):3286. PubMed ID: 28607390
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel Dengue-1 virus replicon system expressing secretory Gaussia luciferase for analysis of viral replication and discovery of antiviral drugs.
Kato F; Kobayashi T; Tajima S; Takasaki T; Miura T; Igarashi T; Hishiki T
Jpn J Infect Dis; 2014; 67(3):209-12. PubMed ID: 24858611
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
[TBL] [Abstract][Full Text] [Related]
10. Construction of self-replicating subgenomic West Nile virus replicons for screening antiviral compounds.
Alcaraz-Estrada SL; Reichert ED; Padmanabhan R
Methods Mol Biol; 2013; 1030():283-99. PubMed ID: 23821276
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
12. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen.
Gu B; Ouzunov S; Wang L; Mason P; Bourne N; Cuconati A; Block TM
Antiviral Res; 2006 Jun; 70(2):39-50. PubMed ID: 16724398
[TBL] [Abstract][Full Text] [Related]
13. A Unique Robust Dual-Promoter-Driven and Dual-Reporter-Expressing SARS-CoV-2 Replicon: Construction and Characterization.
Liu Y; Li L; Timani KA; He JJ
Viruses; 2022 May; 14(5):. PubMed ID: 35632716
[TBL] [Abstract][Full Text] [Related]
14. Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen.
Liu S; Chou CK; Wu WW; Luan B; Wang TT
J Virol; 2022 Mar; 96(6):e0221621. PubMed ID: 35080424
[TBL] [Abstract][Full Text] [Related]
15. Potential high-throughput assay for screening inhibitors of West Nile virus replication.
Lo MK; Tilgner M; Shi PY
J Virol; 2003 Dec; 77(23):12901-6. PubMed ID: 14610212
[TBL] [Abstract][Full Text] [Related]
16. Development of a replicon cell line-based high throughput antiviral assay for screening inhibitors of Zika virus.
Li JQ; Deng CL; Gu D; Li X; Shi L; He J; Zhang QY; Zhang B; Ye HQ
Antiviral Res; 2018 Feb; 150():148-154. PubMed ID: 29288699
[TBL] [Abstract][Full Text] [Related]
17. Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses.
Lim TW; Yuan J; Liu Z; Qiu D; Sall A; Yang D
Curr Opin Mol Ther; 2006 Apr; 8(2):104-7. PubMed ID: 16610761
[TBL] [Abstract][Full Text] [Related]
18. The combined use of alphavirus replicons and pseudoinfectious particles for the discovery of antivirals derived from natural products.
Delekta PC; Raveh A; Larsen MJ; Schultz PJ; Tamayo-Castillo G; Sherman DH; Miller DJ
J Biomol Screen; 2015 Jun; 20(5):673-80. PubMed ID: 25550354
[TBL] [Abstract][Full Text] [Related]
19. Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities.
Takazawa S; Kotaki T; Nakamura S; Utsubo C; Kameoka M
Virus Res; 2023 Sep; 334():199176. PubMed ID: 37473963
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of subgenomic replicons of New York strain of West Nile virus.
Shi PY; Tilgner M; Lo MK
Virology; 2002 May; 296(2):219-33. PubMed ID: 12069521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
